フュージョン生検の世界市場：2023-2030年

世界のフュージョン生検市場は予測期間（2023-2030年）にCAGR 8.4％で成長すると予測されます。フュージョン生検は、磁気共鳴画像法（MRI）と超音波技術を組み合わせて前立腺の疑わしい部位の生検を誘導する低侵襲の手技です。この手技は前立腺がんの診断に使用され、前立腺がんは世界中の男性に最も多くみられるがんです。同市場の主要企業は、より高度な医療と診断のために新技術の市場導入に注力しています。例えば、2023年7月、FUJIFILM Healthcare Europeは、泌尿器科医が生検を効率化できるよう、前立腺フュージョン専用画像を搭載した診断用超音波システムARIETTA 65 IntuitiveFusionを発表しました。同社は、オランダのアムステルダムで最近開催された欧州泌尿器科学会（EAU）でARIETTA 65 IntuitiveFusionを発表しました。このコンパクトなシステムは、独自の超音波エンジンと統合フュージョン・ソフトウェアを搭載し、標的前立腺生検の定位ナビゲーションを可能にします。

セグメントの展望

経直腸サブセグメントが世界のフュージョン生検市場でかなりのシェアを占めると予想されます。

生検ルートの中で、経直腸サブセグメントが世界のフュージョン生検市場でかなりのシェアを占めると予想されます。このセグメント成長の要因は、直腸から行うプロセスなどです。これは前立腺へのアクセスが容易なため、最も一般的なフュージョン生検のタイプです。また、感染リスクが低く、処置時間も短いため、より使用に適しています。このため、この生検ルートに対する戦略的取り組みが増加し、市場プレーヤーは新製品や改良品の開発に注力しています。例えば、2023年1月、Fortis Hospital, Bannerghatta Roadは、前立腺がんの診断と治療を大きく変えるBK超音波MRIフュージョン生検ソリューションの発売を発表しました。ロボット支援手術は低侵襲手術であり、外科医が手術を行う際、より良い視野、精度、制御を可能にします。その他の利点としては、痛みの減少、術後の感染症の減少、傷跡の減少などがあります。回復も早く、入院期間も最小限に抑えられ、より早く動けるようになり、リハビリテーションも早くなります。感染の可能性を減らすことで、糖尿病やその他の合併症を持つ人々にとって理想的な手術となります。

地域別展望

フュージョン生検の世界市場は、欧州は、同地域における前立腺がんの有病率の上昇に起因して、世界市場で突出したシェアを占めると予想されています。Prostate Cancer UKによると、毎年平均52,000人以上の男性が前立腺がんと診断されており、これは毎日144人に相当します。45分に1人の男性が前立腺がんで死亡しており、これは毎年12,000人以上に相当します。

北米地域はフュージョン生検の世界市場において大きなCAGRで成長すると予想される

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、新製品の発売、既存事業の拡大、前立腺がんに対する意識の高まり、人口基盤の増加、同地域の可処分所得水準の上昇に起因しています。米国国立がん研究所によると、前立腺がんの新規罹患率は、男性10万人当たり年間113.4人でした。死亡率は10万人当たり18.8人でした。2017年から2019年のデータに基づくと、男性の約12.9％が生涯のある時点で前立腺がんと診断されます。2020年には、米国で前立腺がんに罹患している男性は3,343,976人と推定されます。したがって、市場プレーヤーは、この地域でがん治療のための新製品を継続的に導入しています。例えば、2023年6月、Hoag社は、非侵襲的ロボット高密度焦点式超音波（HIFU）技術であるFocal Oneのイントロダクションより、限局性前立腺がんの男性に病気との闘いにおける新たな治療オプションを提供しています。HIFUは、前立腺のがん組織を正確に狙い撃ちする先端技術で、泌尿器外科医は前立腺の病変部分だけを切除、つまり破壊することができます。その結果、排尿や勃起の副作用など、前立腺全体の治療に伴う多くの副作用を伴わないがん治療が可能になります。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• ESAOTE SpA
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Koninklijke Philips N.V.
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• UC-Care Medical Systems Ltd.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• フュージョン生検の世界市場：生検ルート別
  • 経直腸
  • 経会陰
• フュージョン生検の世界市場：用途別
  • 病院
  • 診断センター
  • 外来医療センター

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Eigen Health
• Focal Healthcare
• GeoScan Medical
• Hitachi Ltd.
• innoMedicus Ltd
• KOELIS
• MEDCOM Sp. z o. o

LIST OF TABLES

• 1. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
• 2. GLOBAL TRANSRECTAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
• 3. GLOBAL TRANSPERINEAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
• 4. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
• 5. GLOBAL FUSION BIOPSY FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 6. GLOBAL FUSION BIOPSY FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 7. GLOBAL FUSION BIOPSY FOR AMBULATORY CARE CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 8. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 9. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 10. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
• 11. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
• 12. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 13. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
• 14. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
• 15. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 16. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
• 17. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
• 18. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 19. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
• 20. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL FUSION BIOPSY MARKET SHARE BY BIOPSY ROUTE, 2022 VS 2030 (%)
• 2. GLOBAL TRANSRECTAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL TRANSPERINEAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL FUSION BIOPSY MARKET SHARE BY END-USE, 2022 VS 2030 (%)
• 5. GLOBAL FUSION BIOPSY FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL FUSION BIOPSY FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL FUSION BIOPSY FOR AMBULATORY CARE CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. US FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 10. CANADA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 11. UK FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 12. FRANCE FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 13. GERMANY FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 14. ITALY FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 15. SPAIN FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 16. REST OF EUROPE FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 17. INDIA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 18. CHINA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 19. JAPAN FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 20. SOUTH KOREA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 21. REST OF ASIA-PACIFIC FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
• 22. REST OF THE WORLD FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)

Global Fusion biopsy Market Size, Share & Trends Analysis Report by Biopsy Route (Transrectal and Transperineal), and by End User (Hospitals, Diagnostic Centers and Ambulatory Care Centers), Forecast Period (2023-2030)

The global fusion biopsy market is anticipated to grow at a CAGR of 8.4% during the forecast period (2023-2030). Fusion biopsy is a minimally invasive procedure that uses a combination of magnetic resonance imaging (MRI) and ultrasound technology to guide the biopsy of suspicious areas in the prostate gland. This procedure is used to diagnose prostate cancer, which is the most common cancer among men worldwide. The major players in the market are focusing on introducing new technology in the market for better advanced medical treatment and diagnosis. For instance, in July 2023, FUJIFILM Healthcare Europe unveiled the ARIETTA 65 IntuitiveFusion, a diagnostic ultrasound system with dedicated prostate fusion imaging to help urologists streamline biopsies. FUJIFILM Healthcare Europe launched the ARIETTA 65 IntuitiveFusion at the recent European Association of Urology (EAU) congress in Amsterdam, the Netherlands. This compact system is powered by ultrasound unique engine and integrated fusion software to allow stereotactic navigation of targeted prostate biopsies.

Segmental Outlook

The global fusion biopsy market is segmented on the biopsy route, and end user. Based on the biopsy route, the market is sub-segmented into transrectal and transperineal. Based on the end user, the market is sub-segmented into hospitals, diagnostic centers and ambulatory care centers. Among the end-user, the hospital sub-segment is anticipated to hold a considerable share of the market, owing to high purchasing power. The average unit price of a fusion biopsy system is high, making it unaffordable for private diagnostic centers.

The Transrectal Sub-Segment is Anticipated to Hold a Considerable Share of the Global Fusion biopsy Market

Among the biopsy route, the transrectal sub-segment is expected to hold a considerable share of the global Fusion biopsy market. This segmental growth is attributed to factor includes, the process performed through the rectum. This is the most common type of fusion biopsy, as it allows for easy access to the prostate gland. Also, it has lower risk of infection and shorter procedure time which make it more suitable to use. It lead to increase in strategic initiatives for this Biopsy Route and market players are focusing on developing new and improved products. For instance, in January 2023, Fortis Hospital, Bannerghatta Road announced the launch of BK ultrasound MRI Fusion Biopsy solution, a game changer in Prostate cancer diagnosis and treatment. Robot-aided surgery is a minimally invasive procedure which allows surgeons to have better vision, precision, and control while performing the surgeries. Other benefits include decreased pain, fewer post-operative infections and less scarring. Recovery is rapid, with minimal hospital stay, faster mobilization and rehabilitation. Reducing the chance of infection makes it an ideal procedure for people with diabetes and other co-morbidities.

Regional Outlook

The global fusion biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to rising prevalence of prostate cancer in the region. According to Prostate Cancer UK, more than 52,000 men are diagnosed with prostate cancer every year on average - that is 144 men every day. Every 45 minutes one man dies from prostate cancer - that is more than 12,000 men every year.

The North America Region is Expected to Grow at a Significant CAGR in the Global Fusion biopsy Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to new product launches, expansion of already existing business, rising awareness of prostate cancer, increasing population base, and rising disposable income levels in the region. According to National Cancer Institute, the rate of new cases of prostate cancer was 113.4 per 100,000 men per year. The death rate was 18.8 per 100,000 men per year. Approximately 12.9 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2017- 2019 data. In 2020, there were an estimated 3,343,976 men living with prostate cancer in the United States. Hence, the market players are continuously introducing new product for cancer treatment in the region. For instance, in June 2023, Hoag is giving men with localized prostate cancer an additional treatment option in the battle against disease with the introduction of Focal One, a non-invasive robotic High Intensity Focused Ultrasound (HIFU) technology. An advanced technology that precisely targets cancerous prostate tissue, HIFU allows urologic surgeons to ablate, or destroy, just the diseased portion of the prostate. The result is a cancer treatment without many of the side effects that come with treating the entire prostate, including urinary and erectile side effects.

Market Players Outlook

The major companies serving the fusion biopsy market include Eigen Health, ESAOTE SpA, Focal Healthcare, GeoScan Medical, Hitachi Ltd., KOELIS, Koninklijke Philips N.V., MedCom, UC-Care Medical Systems Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2022, Promaxo, Inc. announced it has entered into research collaborations with leading European university hospitals, Imperial College London and University Hospital Tuebingen Germany, for MR guided prostate interventions. In collaboration with Imperial College London, Promaxo received a grant and entered into a research agreement for a clinical study comparing Promaxo's portable MRI and TRUS-Fusion biopsy to assess for accuracy in prostate cancer detection.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global fusion biopsy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. ESAOTE SpA
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Koninklijke Philips N.V.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. UC-Care Medical Systems Ltd.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Fusion biopsy Market by Biopsy Route
  • 4.1.1. Transrectal
  • 4.1.2. Transperineal
• 4.2. Global Fusion biopsy Market by End-use
  • 4.2.1. Hospitals
  • 4.2.2. Diagnostic Centers
  • 4.2.3. Ambulatory Care Centers

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Eigen Health
• 6.2. Focal Healthcare
• 6.3. GeoScan Medical
• 6.4. Hitachi Ltd.
• 6.5. innoMedicus Ltd
• 6.6. KOELIS
• 6.7. MEDCOM Sp. z o. o